Teleflex (NYSE:TFX) Rating Increased to Neutral at Bank of America

Bank of America upgraded shares of Teleflex (NYSE:TFX) from an underperform rating to a neutral rating in a research note issued to investors on Monday, MarketBeat reports. The brokerage currently has $135.00 target price on the medical technology company’s stock.

A number of other equities research analysts have also issued reports on the company. Wells Fargo & Company increased their price target on Teleflex from $116.00 to $130.00 and gave the company an “equal weight” rating in a research report on Friday, February 27th. Needham & Company LLC increased their price target on Teleflex from $138.00 to $147.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. Wall Street Zen lowered Teleflex from a “hold” rating to a “sell” rating in a research report on Saturday, March 7th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Teleflex in a research report on Friday, March 27th. Finally, Truist Financial increased their price target on Teleflex from $120.00 to $135.00 and gave the company a “hold” rating in a research report on Thursday, December 18th. Three analysts have rated the stock with a Buy rating, five have given a Hold rating and two have given a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $138.50.

Teleflex Price Performance

TFX opened at $123.22 on Monday. The stock’s 50-day moving average price is $112.24 and its 200 day moving average price is $116.05. Teleflex has a 12-month low of $100.18 and a 12-month high of $138.93. The company has a current ratio of 2.54, a quick ratio of 2.01 and a debt-to-equity ratio of 0.81. The firm has a market cap of $5.45 billion, a price-to-earnings ratio of -6.00, a PEG ratio of 0.74 and a beta of 0.84.

Teleflex (NYSE:TFX) last posted its earnings results on Thursday, February 26th. The medical technology company reported $1.93 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.73 by ($1.80). Teleflex had a positive return on equity of 14.30% and a negative net margin of 30.56%.The firm had revenue of $569.00 million for the quarter, compared to analyst estimates of $912.57 million. During the same period in the previous year, the company posted $3.89 EPS. Teleflex’s revenue was down 28.5% on a year-over-year basis. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. As a group, sell-side analysts expect that Teleflex will post 13.98 earnings per share for the current year.

Teleflex Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, March 31st. Stockholders of record on Friday, March 6th were given a dividend of $0.34 per share. This represents a $1.36 annualized dividend and a dividend yield of 1.1%. The ex-dividend date of this dividend was Friday, March 6th. Teleflex’s dividend payout ratio (DPR) is -6.62%.

Institutional Investors Weigh In On Teleflex

Several hedge funds and other institutional investors have recently made changes to their positions in TFX. Empowered Funds LLC grew its stake in Teleflex by 15.8% during the 1st quarter. Empowered Funds LLC now owns 1,684 shares of the medical technology company’s stock worth $233,000 after buying an additional 230 shares during the last quarter. Jane Street Group LLC grew its stake in Teleflex by 42.6% during the 1st quarter. Jane Street Group LLC now owns 6,343 shares of the medical technology company’s stock worth $877,000 after buying an additional 1,895 shares during the last quarter. American Century Companies Inc. grew its stake in Teleflex by 32.7% during the 2nd quarter. American Century Companies Inc. now owns 13,640 shares of the medical technology company’s stock worth $1,614,000 after buying an additional 3,360 shares during the last quarter. Invesco Ltd. grew its stake in Teleflex by 1.2% during the 2nd quarter. Invesco Ltd. now owns 135,516 shares of the medical technology company’s stock worth $16,040,000 after buying an additional 1,659 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in Teleflex by 108.1% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,003 shares of the medical technology company’s stock worth $119,000 after buying an additional 521 shares during the last quarter. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.